Treatment of locally advanced non-small cell lung cancer

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 7, 2009, Pages

  Fidler, Mary Jo ^a   Kim, Anthony W ^a   Zusag, Thomas ^a   Bonomi, Philip ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Lung cancer; Radiation

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; IFOSFAMIDE; LOMUSTINE; MITOMYCIN; PACLITAXEL; PEMETREXED; PLACEBO; VINBLASTINE; VINDESINE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; ENDOBRONCHIAL ULTRASONOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGITIS; EVIDENCE BASED PRACTICE; GRANULOCYTOPENIA; HEMOPTYSIS; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; TRACHEOESOPHAGEAL FISTULA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RADIOTHERAPY;

EID: 70349513278     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009 June 9.
2. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940-945.
3. Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO (american society for therapeutic radiology and oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients. GETCB (groupe d'etude et traitement des cancers bronchiques), FNCLCC (federation nationale des centres de lutte contre le cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys. 1991;20:1183-1190.
4. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254-261.
5. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol. 2004;22:2357-2362.
6. Reed CE, Harpole DH, Posther KE, et al. Results of the american college of surgeons oncology group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126:1943-1951, 2003
7. Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:178S-201S.
8. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis. Ann Intern Med. 2003;139:879-892.
9. Serra M, Cirera L, Rami-Porta R, et al. Routine positron emission tomography (PET) and selective mediastinoscopy is as good as routine mediastinoscopy to rule out N2 disease in non-small cell lung cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24:Abst 7031.
10. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial. Lancet. 2002;359: 1388-1393.
11. Detterbeck FC, Jantz MA, Wallace M, et al. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:202S-220S.
12. Rintoul RC, Tournoy KG, El Daly H, et al. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol. 2009;4:44-48.
13. Kalade AV, Eddie Lau WF, Conron M, et al. Endoscopic ultrasound-guided fine-needle aspiration when combined with positron emission tomography improves specificity and overall diagnostic accuracy in unexplained mediastinal lymphadenopathy and staging of non-small-cell lung cancer. Intern Med J. 2008;38:837-844.
14. Tournoy KG, De Ryck F, Vanwalleghem LR, et al. Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: A randomized trial. Am J Respir Crit Care Med. 2008;177:531-535.
15. Rami-Porta R, Ball D, Crowley J, et al. The IASLC lung cancer staging project: Proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2:593-602.
16. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210-1215.
17. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation therapy oncology group, eastern cooperative oncology group, and southwest oncology group. Chest. 2000;117:358-364.
18. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer. 1995;76:593-601.
19. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524-530.
20. Trovo MG, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1992;24:11-15.
21. Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the cancer and leukemia group B and the eastern cooperative oncology group. J Clin Oncol. 1999;17:4-11.
22. Huber RM, Flentje M, Schmidt M, et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: Study CTRT99/ 97 by the bronchial carcinoma therapy group. J Clin Oncol. 2006;24:4397-4404.
23. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23:5883-5891.
24. Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and leukemia group B. J Clin Oncol. 2007;25:1698-1704.
25. Gervais R, Ducolone A, Lechevalier T, et al. Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT) [vinorelbine (Vr)-cisplatine (P)]: Final results of a randomized phase III trial in stage III unresectable non small cell lung (NSCLC) cancer. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol (ASCO Annual Meeting Abstracts). 2005;23:Abst 7016.
26. Vokes EE. Optimal therapy for unresectable stage III non-small-cell lung cancer. J Clin Oncol 2005;23:5853-5855.
27. Curran WJ, Scott CB, Langer CJ. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol. 2003;22: Abstr 2499.
28. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692-2699.
29. Kiura K, Takigawa N, Segawa H, et al. Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer: OLCSG 0007. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abstr 7515.
30. Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A southwest oncology group phase II study, SWOG 9019. J Clin Oncol. 2002;20:3454-3460.
31. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II southwest oncology group study S9504. J Clin Oncol. 2003;21:2004-2010.
32. Hanna N, Neubauer MA, Ansari RH, et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25:Abst 7512.
33. Mina LA, Neubauer MA, Ansari RH, et al. Phase III trial of cisplatin plus etoposide plus concurrent chest radiation with or without consolidatin docetaxel in patients with inoperable stage III non-small cell lung cancer: HOG LUN 01-24/USO-023-updated results. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abst 7519.
34. Seiwert TY, Connell PP, Mauer AM, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007;13:515-522.
35. Pirker R, Szczesna A, von Pawel J, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abst 3.
36. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 2000;18:47S-53S.
37. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Enlg J Med. 2009;360:1408-1417.
38. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
39. Govindan R, Bogart J, Wang X, et al. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407-early evaluation of feasibility and toxicity. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abst 7518.
40. Blumenschein GR, Paulus R, Curran WJ, et al. phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abst 7516.
41. Blackstock A, Petty J, Oaks T, et al. Gefitinib (ZD-1839) with concurrent docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel/gefitinib for patients with stage III NSCLC: A phase I study. J Clin Oncol. 2007;25:Abst 18165.
42. Rischin D, Burmeister B, Mitchell P, et al. Phase I trial of gefitinib in combination with concurrent carboplatin, paclitaxel and radiation therapy in stage III non-small cell lung cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2004;22:Abst 7077
43. Ready N, Janne P, Herndon J. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer: A CALGB stratified phase II trial. J Clin Oncol. 2006;24:7046.
44. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol. 2008;26:2450-2456.
45. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
46. Citrin D, Menard C, Camphausen K: Combining radiotherapy and angiogenesis inhibitors: Clinical trial design. Int J Radiat Oncol Biol Phys. 2006;64:15-25.
47. Frederick B, Gustafson D, Bianco C, et al. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:33-37.
48. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001;61:2413-2419.
49. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374-3378.
50. Kozin SV, Boucher Y, Hicklin DJ, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 2001;61:39-44.
51. Li J, Huang S, Armstrong EA, et al. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys. 2005;62:1477-1485.
52. O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol. 2006;16:45-50.
53. Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys. 2007;67:1526-1537.
54. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6: 553-563.
55. Socinski MA, Morrison L, Stinchcombe TE, et al. Incorporation of bevacizumab and erlotinib with induction and concurrent carboplatin/ paclitaxel and 74Gy of thoracic radiotherapy in stage III non-small cell lung cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abst 7517
56. Choong NW, Vokes EE, Haraf DJ, et al. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008;3:59-67.
57. Bradley JD, Graham M, Suzanne S, et al. Phase I results of RTOG L-0117: A phase I/II dose intensification study using 3dCRT and concurrent chemotherapy for patients with inoperable NSCLC. J Clin Oncol (ASCO Annual Meeting Abstracts). 2005;23:Abst 7063.
58. Schild S: Results of a phase I/II trial of concurrent chemotherapy and escalating doses of radiation for unresectable non small cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:S44.
59. Lau DH, Crowley JJ, Gandara DR, et al. Southwest oncology group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol. 1998;16:3078-3081.
60. Davies AM, Chansky K, Lau DH, et al. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 2006;24:5242-5246.
61. Bradley JD, Scott CB, Paris KJ, et al. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). Int J Radiat Oncol Biol Phys. 2002;52:1173-1179.
62. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys. 1999;45:1143-1149.
63. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 2000;48:1475-1482.
64. Firat S, Byhardt RW, Gore E. Comorbidity and karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies. radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 2002;54:357-364.
65. Semrau S, Klautke G, Virchow JC, et al. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy. Respir Med. 2008;102:210-218.
66. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst. 2002;94: 173-181.
67. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570-5577.
68. Edelman MJ, Tang M, Gardner JF, et al. Therapy (Tx) of locally advanced (LA) NSCLC in the elderly: Analysis of 6,325 patients from Surveillance, Epidemiology and End Results (SEER)-Medicare, and end results (SEER)-medicare. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abst 7549.
69. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673-680.
70. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153-158.
71. Johnstone DW, Byhardt RW, Ettinger D, et al. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01 radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 2002;54:365-369.
72. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of southwest oncology group phase II study 8805. J Clin Oncol. 1995;13:1880-1892.
73. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-smal cell lung cancer: Outcomes update of north American intergroup 0139 (RTOG 9309). J Clin Oncol (ASCO Annual Meeting Abstracts). 2005;23:624s
74. van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442-450.
75. Uy KL, Darling G, Xu W, et al. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;134:188-193.
76. Edelman MJ, Suntharalingam M, Burrows W, et al. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg. 2008;86:903-910.
77. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: Long-term results of southwest oncology group trial 9416 (intergroup trial 0160). J Clin Oncol. 2007;25:313-318.
78. Kunitoh H, Kato H, Tsuboi M, et al. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: Report of Japan Clinical Oncology Group trial 9806. J Clin Oncol. 2008;26:644-649.
79. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991;83:417-423.